UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
MWN-AI** Summary
Unicycive Therapeutics, Inc. has announced the FDA's acceptance of its resubmission for the New Drug Application (NDA) of oxylanthanum carbonate (OLC), an investigational oral phosphate binder intended for treating hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. The FDA has classified this resubmission as Class II, entailing a six-month review period, with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026.
Dr. Shalabh Gupta, CEO of Unicycive, expressed optimism over the FDA’s timely acceptance and mentioned that the company is proactively preparing for a potential launch of OLC this year, which could provide critical treatment options for CKD patients grappling with high phosphate levels. The NDA is supported by data from three clinical studies, along with preclinical studies and relevant chemistry, manufacturing, and controls (CMC) data. Notably, the FDA raised no concerns regarding the safety or efficacy data in previous submissions.
As of the end of 2025, Unicycive reported an unaudited cash position of $41.3 million, expected to sustain operations into 2027 while supporting commercialization efforts for OLC. This investigational drug is notable for leveraging proprietary nanoparticle technology, which promises high phosphate binding efficacy and a reduced pill burden compared to existing therapies, potentially enhancing patient adherence.
Hyperphosphatemia is a significant medical challenge for patients with End Stage Renal Disease (ESRD), with many requiring medications to control phosphate levels. The effective management of this condition is crucial, as uncontrolled hyperphosphatemia is linked to increased mortality and hospitalizations among CKD patients on dialysis.
Unicycive is a clinical-stage biotechnology firm, focused on developing innovative treatments for kidney diseases, with its principal candidate OLC standing out due to its potential best-in-class profile and robust patent protections.
MWN-AI** Analysis
Unicycive Therapeutics (Nasdaq: UNCY) has recently made headlines with the FDA's acceptance of its New Drug Application (NDA) resubmission for oxylanthanum carbonate (OLC), an investigational oral phosphate binder aimed at treating hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. With a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026, investors should closely monitor the unfolding regulatory landscape as Unicycive prepares for a potential product launch within the next year.
The company's unaudited cash position of $41.3 million as of the end of 2025, which extends its financial runway into 2027, suggests that it is well-positioned to finance ongoing commercialization efforts for OLC and other drug development projects. Given the urgency of treating hyperphosphatemia — a condition affecting nearly all patients with end-stage renal disease — OLC could fill a significant market demand, particularly given its differentiation as a potentially best-in-class therapy requiring fewer pills for patients.
The positive momentum surrounding the NDA resubmission, noted by the absence of concerns regarding prior clinical data, enhances investor sentiment. However, stakeholders should remain cognizant of potential risks that could impact the drug's approval and market adoption, including competition from established therapies, dependence on third-party manufacturers, and broader regulatory hurdles.
For investors considering Unicycive, the next six months leading up to the PDUFA date will be critical. Keeping an eye on market sentiment, regulatory developments, and any strategic partnerships that may arise could provide valuable insights. As the company navigates the intersection of clinical success and commercialization readiness, maintaining a diversified investment portfolio and monitoring wider sector trends in biotechnology could mitigate risks while capitalizing on potential upside associated with OLC's market introduction.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- FDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 29, 2026
- Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027
LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The Agency has deemed the OLC resubmission to be a Class II complete response which has a six-month review period from the date of resubmission and set a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026.
“We are pleased that the agency has promptly accepted the resubmission of our NDA for OLC,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “We are advancing our commercial preparation activities in anticipation of a potential launch of OLC later this year, to help provide an important treatment option to patients with chronic kidney disease (CKD) on dialysis who continue to struggle with hyperphosphatemia.”
The NDA is supported by data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies as well as chemistry, manufacturing and controls (CMC) data. The FDA did not raise any concerns regarding OLC’s preclinical, clinical, or safety data included in the original NDA submission.
The Company ended 2025 with an unaudited position of $41.3 million in cash, cash equivalents, and short-term investments, which permits continued advancement of OLC commercial launch activities and a cash runway into 2027.
About Oxylanthanum Carbonate (OLC)
OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden.
Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035.
About Hyperphosphatemia
Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.1 Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.
1Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information about Unicycive, visit Unicycive.com and follow us on LinkedIn and X.
Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; our need to raise substantial additional capital in the future to fund our continuing operations and the development and commercialization of our current product candidates and future product candidates; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; risks related to delays in obtaining or failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; and our failure, or the failure of our third-party manufacturers, or their subcontractors, to comply with cGMPs or other applicable regulations, which could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Layne Litsinger
Real Chemistry
llitsinger@realchemistry.com
SOURCE: Unicycive Therapeutics, Inc.
FAQ**
What milestones does Unicycive Therapeutics Inc. (UNCY) anticipate achieving prior to the FDA's PDUFA target date of June 29, 2026, for oxylanthanum carbonate (OLC)?
How does Unicycive Therapeutics Inc. (UNCY) plan to utilize its unaudited cash position of $41.3 million to support OLC's potential commercial launch activities?
What specific factors contribute to Unicycive Therapeutics Inc. (UNCY) projecting a cash runway into 2027, despite the uncertainties in the biotech sector?
How does Unicycive Therapeutics Inc. (UNCY) intend to address potential competition for OLC once it gains FDA approval for treating hyperphosphatemia in CKD patients on dialysis?
**MWN-AI FAQ is based on asking OpenAI questions about Unicycive Therapeutics Inc. (NASDAQ: UNCY).
NASDAQ: UNCY
UNCY Trading
4.6% G/L:
$6.82 Last:
162,932 Volume:
$6.51 Open:
